On day þ 73 after allogeneic PBSC transplantation (alloSCT), a 47-year-old female patient was admitted to our transplantation ward with severe pain in her left knee. Transplantation was performed in October 2012 in the first CR of secondary AML with a complex aberrant karyotype after two induction cycles (ICE protocol). A full-match (10/10) unrelated PBSC graft was transplanted after FLAMSA/ATG conditioning. 1 Immunosuppressive treatment consisted of CsA and mycophenolate mofetil. The patient received posaconazole (3 Â 200 mg/day) as antifungal prophylaxis starting from the day after terminating conditioning. Hematopoietic engraftment was achieved by day þ 19, and on day þ 20 full-donor chimerism was detectable. No significant infectious complications appeared during the hospital stay and the patient was discharged without any signs of acute GVHD on day þ 25. Microbial-surveillance urine testing revealed Candida krusei without any clinical signs of infection. Thus, no specific treatment was initiated and subsequent testings remained negative for fungal and/or bacterial growth. Mycophenolate mofetil was reduced starting on day þ 30 and was removed by day þ 51; CsA taper started on day þ 54 without any signs of acute GVHD due to the high relapse risk constellation. On the day of her admission to our ward, the joint was markedly swollen due to an articular effusion, slightly warmed but not reddened, and no other joints were affected. Owing to elevated laboratory results indicating infection, we immediately initiated antibiotic therapy with meropenem and linezolid while maintaining immunosuppressive CsA taper (actual levels B40 ng/mL) and antifungal prophylaxis. An MRI of the knee on day þ 75 showed articular effusion, synovitis and a big ganglion cyst (Figure 1a ). Of note, no pre-existing arthrosis was reported. During the antibiotic therapy, infectious parameters transiently decreased but clinical symptoms persisted. We therefore initiated puncture of the articular effusion on day þ 78, which revealed the growth of C. krusei. Antifungal prophylaxis was immediately switched to antifungal therapy using liposomal amphotericin B (3 mg/kg/day) according to the IDSA (Infectious Diseases Society of America) Guidelines. 2 To date, only limited data are available on the sensitivity of C. krusei to posaconazole. 3 As pharmacokinetic measurements were not evaluated in her daily routine, we further hypothesized that blood levels could have been too low to prevent infection. Nevertheless, in vitro testing of antifungal drug sensitivity in our case revealed sensitivity to posaconazole, supporting the idea of insufficient drug availability. Unfortunately, the volume of synovial fluid was not sufficient to quantify intraarticular drug levels of posaconazole. Owing to an insufficient clinical improvement, we subsequently escalated antifungal treatment to the combination of liposomal amphotericin B and caspofungin, which was also tested to be effective and is recommended as the treatment alternative in the IDSA Guidelines and as the first-line recommendation for invasive candidiasis in the ECIL Guidelines. 2, 4 In this particular case, combination therapy was selected to achieve maximal efficacy and to avoid surgical debridement, which is recommended in the IDSA Guideline and was suggested by the orthopedic surgeons. However, because of the relatively early time point after allo-SCT (day þ 80) with ongoing immunosuppressive medication, surgical intervention was not favored and the combined antifungal treatment was continued. Other manifestations or foci of fungal infection were excluded using whole-body computed tomography scan, transesophageal echocardiography and ophthalmological control. Owing to the rising infection levels, we subsequently switched to a combination therapy of voriconazole together with anidulafungin, as the isolated C. krusei showed very low minimalinhibitory concentrations in vitro and voriconazole might be superior in regard to its diffusion into the articular cavity. Owing to limited improvement of articular pain (especially during walking), we subsequently performed an MRI of the joint on day þ 92, which now showed signs of massive worsening with a more pronounced enrichment of contrast agent due to edema in the tibia. These changes were interpreted as suspected fungal osteomyelitis with concomitant myositis of the popliteal muscle (Figure 1b) . Thus, we next decided to perform an arthroscopy to sample effusion as well as synovial and bone tissues to ascertain the diagnosis of C. krusei arthritis with subsequent osteomyelitis before an extensive surgical debridement was performed. The anidulafungin and voriconazole combination antifungal therapy was continued and an antibiotic therapy was initiated on the day of surgery for 10 days. Of note, all specimen (effusion, synovia and bone) were negative for fungal species as detected by culture, PCR and histomorphology (PAS and Grocott staining). In addition, no bacterial infection could be detected. Thus, we interpreted the inflammatory signs seen in the MRI as infection-triggered inflammation (not fulfilling the classical criteria of musculoskeletal or joint GVHD) and subsequently started steroid therapy (1 mg/kg body weight). In parallel, a combination antifungal therapy was continued.
This led to a dramatic improvement of clinical symptoms, allowing remobilization of the patient and her discharge on day þ 107 with rapidly decreasing inflammatory signs. Drug levels of voriconazole were adequate (2555 ng/mL) after switching to oral application. Steroids were subsequently tapered and voriconazol subscribed for another 3 months. The patient now is without clinical symptoms and all inflammatory parameters are in the normal range.
Only a few cases of conservative treatment of isolated C. krusei monoarthritis in hematological patients are available. 5, 6 To our knowledge, our report is the first one to describe this complication after allo-SCT. Current guidelines recommend antifungal therapy in combination with surgery. 4 We here show that aggressive antifungal therapy can successfully treat fungal infection. Moreover, radiological and clinical signs of worsening may be triggered by an inflammatory response sensitive to steroids. Careful evaluation by extensive sampling from inflamed regions and microbiological testing should precede the use of steroids, as these may aggravate the situation in case of persisting fungal infection. Finally, it remains elusive whether a compliance problem, insufficient drug absorption or limited local penetration of posaconazole into the articular cavity initially allowed fungal growth in the knee of our patient. The case highlights that regular blood level screening might be useful to select patients at risk of fungal infections due to insufficient posaconazole blood levels. These patients could benefit from individualized dosing schedules or alternative antifungal prophylaxis strategies (that is, voriconazole). 
